Amgen's $28 Billion Bet on Horizon Just Got a Whole Lot Smarter

Amgen hasn't released detailed numerical data yet (effect sizes, dose breakdowns, full secondary endpoints), which leaves some questions unanswered. But a clean primary endpoint hit in a pivotal trial for a disease with no approved treatments? That's a strong hand to play.

Why This Validates a $28 Billion Gamble

When Amgen closed its $27.8 billion acquisition of Horizon Therapeutics in October 2023, skeptics weren't hard to find. The deal was primarily about commercial products: Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for a rare neurological condition. These were solid, revenue-generating assets, but the FTC slapped restrictions on how Amgen could bundle them in formulary negotiations, limiting some of the deal's commercial upside.

Buried in the pipeline, though, was dazodalibep. At the time, it was an interesting but unproven autoimmune candidate. Now it's looking like the sleeper asset of the entire acquisition.

A first-in-class approval in Sjögren's disease would give Amgen something money can't easily buy: a foothold in a completely untapped autoimmune market. No approved disease-modifying therapies means no entrenched competitors. The first company to get a drug across the finish line essentially gets to define the market.

The Scoreboard Isn't Final Yet

Before anyone starts printing "Mission Accomplished" banners, there's a critical caveat. Analysts (including those at William Blair) expect that Amgen will need two positive Phase 3 trials to support an FDA filing. OASIZ 301 is one. The second, OASIZ 303, is still in progress.

And OASIZ 303 isn't just a carbon copy of the first trial. It's testing dazodalibep in a different patient population: people with moderate-to-severe symptom burden but lower systemic disease activity. That distinction matters because Sjögren's patients aren't all the same. Some have widespread organ involvement; others are drowning in fatigue and dryness without the systemic markers to match. A drug that works in both groups would earn a much broader label, and a much bigger commercial opportunity.

Results from OASIZ 303 are expected later in 2026, making it one of the most closely watched readouts on Amgen's calendar.

A Crowded Race With No Winner (Yet)

Amgen isn't the only company chasing Sjögren's. The field has gotten surprisingly competitive over the past two years, with more than a dozen pipeline drugs from at least ten companies in various stages of development.

The closest rival is Novartis, whose drug ianalumab (targeting B cells through the BAFF receptor) has already posted positive results in two Phase 3 studies called NEPTUNUS-1 and NEPTUNUS-2. That puts Novartis arguably ahead in the race to file first. Bristol-Myers Squibb launched a study of its TYK2 inhibitor deucravacitinib in active Sjögren's in late 2023, and Johnson & Johnson's nipocalimab (an FcRn blocker) is also advancing.

The diversity of approaches is actually good news for patients. Different mechanisms will likely work better for different people, and a market with multiple approved options is healthier than a monopoly. For Amgen, the strategic question is whether dazodalibep's CD40L-blocking mechanism can differentiate on efficacy, safety, or both.

The Bottom Line

This is the kind of result that transforms how people think about an acquisition. A $28 billion deal that looked like a portfolio play for existing commercial products now has a genuine pipeline catalyst with first-in-class potential in a disease that affects millions of people worldwide.

Amgen's stock moved higher on the news, and analyst commentary was bullish, if conditional. The consensus: the OASIZ 301 win de-risks dazodalibep significantly, but the real valuation unlock comes when OASIZ 303 reads out. One positive pivotal trial is encouraging. Two would be a green light for regulators.

For Sjögren's patients who have spent years managing symptoms without any real hope of treating the root cause, this data represents something rare in medicine: genuine progress. And for Amgen, it's proof that sometimes the best assets in a mega-deal are the ones nobody was paying attention to.

The Heart Drug That Just Rewrote the Rules for Sick Teenagers

For the first time ever, the FDA has approved a drug specifically for teenagers with obstructive hypertrophic cardiomyopathy. The clinical data behind Camzyos's pediatric expansion is striking, and the competitive implications for Bristol Myers Squibb are even more interesting.